GEN Exclusives

More »

GEN News Highlights

More »
May 29, 2012

Genentech, Ensemble Partner on Macrocyclic Drug Development

  • Roche’s Genentech established a collaboration with Ensemble Therapeutics focused on identifying macrocyclic Ensemblin™ drug candidates against specified Genentech targets. Under terms of the deal Genentech will have the right to develop and commercialize lead molecules in return for paying Ensemble an up-front fee, development milestones, and royalties on future sales of relevant products.

    Ensemble Therapeutics is leveraging its DNA-Programmed Chemistry™ (DPC™) platform to develop a class of synthetically engineered small molecule macrocyclic drugs known as Ensemblins, which it claims can address targets including protein-protein interactions, phosphatases, and proteases that aren’t accessible to conventional small molecule drugs. The firm is exploiting the technology both to develop an in-house pipeline of oral candidates against cancer and immuno-inflammatory diseases as well as through drug discovery partnerships.

    In-house R&D is focused largely on identifying Ensemblins that inhibit protein-protein or protein-peptide interactions. It is headed by a preclinical-stage interleukin-17 antagonist, which is in development as a potential candidate for treating inflammatory and autoimmune diseases. Ensemble has Ensemblin discovery and development partnerships ongoing with Bristol-Myers Squibb and Pfizer.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?